o-desmethylvenlafaxine succinate hydrate

Desvenlafaxine succinate hydrate (WY 45233 Succinate) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI).

Frovatriptan succinate hydrate (Frova) is effective in treating the full spectrum of migraine including the associated symptoms of nausea, vomiting, photophobia, and phonophobia. Frovatriptan succinate hydrate can also be used as in mini-prophylaxis in menstrual migraine. Frovatriptan succinate hydrate is a potent, high affinity, selective and orally active 5-HT1B, HT1D receptor agonist and a moderately potent 5-HT7 receptor agonist, with pKi values of 8.6, 8.4, and 6.7, respectively.

3-O-methyl-L-DOPA is a metabolite of L-DOPA , produced by the activity of catechol O-methyltransferase. 3-O-methyl-L-DOPA may have effects of its own or it may compete with the actions of L-DOPA.

Ribociclib succinate hydrate is a highly specific CDK4/6 inhibitor (IC50s: 10 nM and 39 nM, respectively). It also is over 1,000-fold less potent against the cyclin B/CDK1 complex.

Camptothecin-20(S)-O-propionate hydrate, the C20-propionate ester of CPT, serves as a potent anticancer agent and functions as a topoisomerase-I inhibitor [1] [2]. This compound is often referenced by its alternate name, Camptothecin-20-O-propionate.